Kaugelearenenud heledarakulise neeruvähi immuunravi kulutõhusus: tervisetehnoloogia hindamise raport TTH55

dc.contributor.author	Lutsar, Katrin
dc.contributor.author	Alloja, Janika
dc.contributor.author	Oselin, Kersti
dc.contributor.author	Rooväli, Liis
dc.contributor.author	Nurk, Kaarel
dc.contributor.author	Kiivet, Raul-Allan
dc.contributor.author	Jürisson, Mikk
dc.date.accessioned	2022-11-07T09:03:07Z
dc.date.available	2022-11-07T09:03:07Z
dc.date.issued	2022
dc.description	Report in Estonian, summary in English
dc.identifier.isbn	9789985413081
dc.identifier.uri	http://hdl.handle.net/10062/87846
dc.language.iso	est	et
dc.publisher	Tartu Ülikooli peremeditsiini ja rahvatervishoiu instituut	et
dc.rights	openAccess	et
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	tervisetehnoloogiate hindamine	et
dc.subject	health technology assessment
dc.subject.other	tervisetehnoloogia	et
dc.subject.other	neeruvähk	et
dc.subject.other	neerukasvajad	et
dc.subject.other	Eesti	et
dc.subject.other	immuunravi	et
dc.title	Kaugelearenenud heledarakulise neeruvähi immuunravi kulutõhusus: tervisetehnoloogia hindamise raport TTH55	et
dc.title.alternative	Cost-effectiveness of immunotherapy in the treatment of advanced clear-cell renal carcinoma: health technology assessment report HTA55
dc.type	Technical Report	et